Interpreting the APERITIF Randomized Clinical Trial

Дата публикации: 01-08-2026 00:00:00

To the Editor Puymirat and colleagues report the APERITIF randomized clinical trial evaluating rivaroxaban, 2.5 mg, twice daily for 4 weeks added to dual antiplatelet therapy (DAPT) to prevent left ventricular (LV) thrombus after anterior ST-segment elevation myocardial infarction (STEMI). The primary end point—LV thrombus on contrast-enhanced cardiac magnetic resonance (CMR) at 1 month—was neutral, while minor bleeding (Bleeding Academic Research Consortium [BARC] type 1) was increased in the rivaroxaban group.

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	Interpreting the APERITIF Randomized Clinical Trial—Reply	0	10.38	01-08-2026
2	Dual Antiplatelet Therapy Duration in Patients at High Bleeding Risk	0	7.22	01-08-2026
3	Prasugrel—The Default P2Y12 Inhibitor After PCI for ACS?	0	7.98	01-08-2026
4	Right Ventricular Metrics as End Points in Clinical Trials	0	5.8	01-08-2026
5	Coronary Artery Calcium Progression—A Useful Outcome in Clinical Trials?	0	9.46	01-08-2026
6	Lipoprotein(a), Inflammation, and Risk of Coronary Artery Disease and Aortic Valve Stenosis	0	8.36	01-08-2026
7	Twenty-Five–Year Follow-Up of Quantified Mitral Regurgitation	0	15.41	29-07-2026
8	Error in Figure	0	14.84	01-08-2026
9	Toward a Lifetime Strategy for Aortic Valve Replacement—Ariadne’s Thread	0	7.65	01-08-2026
10	JAMA Cardiology	0	7.83	01-08-2026

Классификация: . Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 13.07. Источник: archderm.jamanetwork.com.